Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to
identify biomarkers of disease activity and clinical response.